Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-centre, Randomized Study to Investigate Patient Preference on Dosing in the Once-monthly Ibandronate and the Once-weekly Risedronate in Korean Women With Postmenopausal Osteoporosis. A Six-month, Two-sequence, and Two Period Crossover Study

NCT00405392 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00405392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00405392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-centre, Randomized Study to Investigate Patient Preference on Dosing in the Once-monthly Ibandronate and the Once-weekly Risedronate in Korean Women With Postmenopausal Osteoporosis. A Six-month, Two-sequence, and Two Period Crossover Study
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
March 22, 2007
Completion date
May 27, 2008
Enrollment
365 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis, postmenopausal